Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Cytokine. 2019 Aug;120:85-87. doi: 10.1016/j.cyto.2019.04.015. Epub 2019 Apr 28.

PMID:
31035172
2.

FLT3 ligand plasma levels in acute myeloid leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Haematologica. 2019 Jun;104(6):e240-e243. doi: 10.3324/haematol.2018.209460. Epub 2019 Jan 10. No abstract available.

3.

[Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity].

Ménager J, Gorin JB, Fichou N, Gouard S, Morgenstern A, Bruchertseifer F, Davodeau F, Kraeber-Bodéré F, Chérel M, Gaschet J, Guilloux Y.

Med Sci (Paris). 2016 Apr;32(4):362-9. doi: 10.1051/medsci/20163204014. Epub 2016 May 2. Review. French.

4.

Production and characterization of monoclonal antibodies specific for canine CD138 (syndecan-1) for nuclear medicine preclinical trials on spontaneous tumours.

Diab M, Nguyen F, Berthaud M, Maurel C, Gaschet J, Verger E, Ibisch C, Rousseau C, Chérel M, Abadie J, Davodeau F.

Vet Comp Oncol. 2017 Sep;15(3):932-951. doi: 10.1111/vco.12233. Epub 2016 Apr 14.

PMID:
27076401
5.

Radioimmunotherapy for Treatment of Acute Leukemia.

Bodet-Milin C, Kraeber-Bodéré F, Eugène T, Guérard F, Gaschet J, Bailly C, Mougin M, Bourgeois M, Faivre-Chauvet A, Chérel M, Chevallier P.

Semin Nucl Med. 2016 Mar;46(2):135-46. doi: 10.1053/j.semnuclmed.2015.10.007. Review.

PMID:
26897718
6.

(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.

Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M, Huguet F, Hunault M, Marcais A, Gaschet J, Cherel M, Guillaume T, Delaunay J, Peterlin P, Eveillard M, Thomas X, Ifrah N, Lapusan S, Bodet-Milin C, Barbet J, Faivre-Chauvet A, Ferrer L, Bene MC, Le Houerou C, Goldenberg DM, Wegener WA, Kraeber-Bodéré F.

Lancet Haematol. 2015 Mar;2(3):e108-17. doi: 10.1016/S2352-3026(15)00020-4. Epub 2015 Feb 25.

PMID:
26687796
7.

Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model.

Fichou N, Gouard S, Maurel C, Barbet J, Ferrer L, Morgenstern A, Bruchertseifer F, Faivre-Chauvet A, Bigot-Corbel E, Davodeau F, Gaschet J, Chérel M.

Front Med (Lausanne). 2015 Nov 4;2:76. doi: 10.3389/fmed.2015.00076. eCollection 2015.

8.

Alpha Particles Induce Autophagy in Multiple Myeloma Cells.

Gorin JB, Gouard S, Ménager J, Morgenstern A, Bruchertseifer F, Faivre-Chauvet A, Guilloux Y, Chérel M, Davodeau F, Gaschet J.

Front Med (Lausanne). 2015 Oct 19;2:74. doi: 10.3389/fmed.2015.00074. eCollection 2015.

9.

Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.

Ménager J, Gorin JB, Maurel C, Drujont L, Gouard S, Louvet C, Chérel M, Faivre-Chauvet A, Morgenstern A, Bruchertseifer F, Davodeau F, Gaschet J, Guilloux Y.

PLoS One. 2015 Jun 22;10(6):e0130249. doi: 10.1371/journal.pone.0130249. eCollection 2015.

10.

Using α radiation to boost cancer immunity?

Gorin JB, Guilloux Y, Morgenstern A, Chérel M, Davodeau F, Gaschet J.

Oncoimmunology. 2014 Dec 13;3(9):e954925. eCollection 2014 Oct.

11.

Radioimmunoconjugates for the treatment of cancer.

Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Eugène T, Pallardy A, Frampas E, Carlier T, Ferrer L, Gaschet J, Davodeau F, Gestin JF, Faivre-Chauvet A, Barbet J, Chérel M.

Semin Oncol. 2014 Oct;41(5):613-22. doi: 10.1053/j.seminoncol.2014.07.004. Epub 2014 Jul 22. Review.

PMID:
25440606
12.

Antitumor immunity induced after α irradiation.

Gorin JB, Ménager J, Gouard S, Maurel C, Guilloux Y, Faivre-Chauvet A, Morgenstern A, Bruchertseifer F, Chérel M, Davodeau F, Gaschet J.

Neoplasia. 2014 Apr;16(4):319-28. doi: 10.1016/j.neo.2014.04.002.

13.

Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy.

Gouard S, Pallardy A, Gaschet J, Faivre-Chauvet A, Bruchertseifer F, Morgenstern A, Maurel C, Matous E, Kraeber-Bodéré F, Davodeau F, Chérel M.

Nucl Med Biol. 2014 May;41 Suppl:e30-5. doi: 10.1016/j.nucmedbio.2014.02.008. Epub 2014 Mar 15.

PMID:
24759272
14.

213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma.

Chérel M, Gouard S, Gaschet J, Saï-Maurel C, Bruchertseifer F, Morgenstern A, Bourgeois M, Gestin JF, Bodéré FK, Barbet J, Moreau P, Davodeau F.

J Nucl Med. 2013 Sep;54(9):1597-604. doi: 10.2967/jnumed.112.111997.

15.

Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors.

Rousseau C, Ruellan AL, Bernardeau K, Kraeber-Bodéré F, Gouard S, Loussouarn D, Saï-Maurel C, Faivre-Chauvet A, Wijdenes J, Barbet J, Gaschet J, Chérel M, Davodeau F.

EJNMMI Res. 2011 Sep 1;1(1):20. doi: 10.1186/2191-219X-1-20.

16.

Permissive, nonpermissive HLA-DPB1 epitope disparities and the specificity of T cells infiltrating the skin during acute graft-versus-host disease.

Vié H, Gaschet J, Milpied N.

Blood. 2011 May 26;117(21):5779-81. doi: 10.1182/blood-2011-02-338533. No abstract available.

17.

Molecular screening of interleukin-6 gene promoter and influence of -174G/C polymorphism on breast cancer.

Chérel M, Campion L, Bézieau S, Campone M, Charrier J, Gaschet J, Ricolleau G, Gouraud W, Charbonnel C, Jézéquel P.

Cytokine. 2009 Sep;47(3):214-23. doi: 10.1016/j.cyto.2009.06.011. Epub 2009 Jul 28.

PMID:
19640729
18.

Selection of Epstein-Barr virus specific cytotoxic T lymphocytes can be performed with B lymphoblastoid cell lines created in serum-free media.

Gallot G, Vollant S, Vivien R, Clémenceau B, Ferrand C, Tiberghien P, Gaschet J, Robillard N, Vié H.

Clin Exp Immunol. 2006 Apr;144(1):158-68.

19.

Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes.

Clémenceau B, Congy-Jolivet N, Gallot G, Vivien R, Gaschet J, Thibault G, Vié H.

Blood. 2006 Jun 15;107(12):4669-77. Epub 2006 Mar 2.

20.

T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.

Gallot G, Hamidou MA, Clémenceau B, Gaschet J, Tiberghien P, Ferrand C, Vivien R, Barbarot S, Coste-Burel M, Moreau A, Vié H.

Clin Immunol. 2006 Apr;119(1):79-86. Epub 2006 Jan 4.

PMID:
16386957
21.
22.

Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model.

Berger C, Blau CA, Huang ML, Iuliucci JD, Dalgarno DC, Gaschet J, Heimfeld S, Clackson T, Riddell SR.

Blood. 2004 Feb 15;103(4):1261-9. Epub 2003 Oct 16.

23.

Characterization of coated vesicles that participate in endocytic recycling.

Peters PJ, Gao M, Gaschet J, Ambach A, van Donselaar E, Traverse JF, Bos E, Wolffe EJ, Hsu VW.

Traffic. 2001 Dec;2(12):885-95.

25.

Case Report: Acute graft-versus-host disease after bone marrow transplantation with a single HLA-DPB1*1001 mismatch: involvement of different TCRBV subsets.

Gaschet J, Gallot G, Ibisch C, Lim A, Even J, Vivien R, Hallet M, Milpied N, Vié H.

Bone Marrow Transplant. 1999 Jun;23(12):1327-1328. No abstract available.

26.

Distribution of ARF6 between membrane and cytosol is regulated by its GTPase cycle.

Gaschet J, Hsu VW.

J Biol Chem. 1999 Jul 9;274(28):20040-5.

27.

Acute graft-versus-host disease after bone marrow transplantation with a single HLA-DPB1*1001 mismatch: involvement of different TCRBV subsets.

Gaschet J, Gallot G, Ibisch C, Lim A, Even J, Vivien R, Hallet MM, Milpied N, Vié H.

Bone Marrow Transplant. 1998 Aug;22(4):385-92. Erratum in: Bone Marrow Transplant 1999 Jun;23(12):1327-8.

28.

Close phenotypic and functional similarities between human and murine alphabeta T cells expressing invariant TCR alpha-chains.

Davodeau F, Peyrat MA, Necker A, Dominici R, Blanchard F, Leget C, Gaschet J, Costa P, Jacques Y, Godard A, Vie H, Poggi A, Romagné F, Bonneville M.

J Immunol. 1997 Jun 15;158(12):5603-11.

PMID:
9190907
29.

Selection of T cells reactive against autologous B lymphoblastoid cells during chronic rheumatoid arthritis.

David-Ameline J, Lim A, Davodeau F, Peyrat MA, Berthelot JM, Semana G, Pannetier C, Gaschet J, Vie H, Even J, Bonneville M.

J Immunol. 1996 Nov 15;157(10):4697-706.

PMID:
8906851
30.

Human HLA-specific T-cell clones with stable expression of a suicide gene: a possible tool to drive and control a graft-versus-host- graft-versus-leukemia reaction?

Gallot G, Hallet MM, Gaschet J, Moreau JF, Vivien R, Bonneville M, Milpied N, Vié H.

Blood. 1996 Aug 1;88(3):1098-103.

31.

Acute graft versus host disease due to T lymphocytes recognizing a single HLA-DPB1*0501 mismatch.

Gaschet J, Lim A, Liem L, Vivien R, Hallet MM, Harousseau JL, Even J, Goulmy E, Bonneville M, Milpied N, Vié H.

J Clin Invest. 1996 Jul 1;98(1):100-7.

32.

HLA-target antigens and T-cell receptor diversity of activated T cells invading the skin during acute graft-versus-host disease.

Gaschet J, Treviño MA, Cherel M, Vivien R, Garcia-Sahuquillo A, Hallet MM, Bonneville M, Harrousseau JL, Bragado R, Milpied N, Vié H.

Blood. 1996 Mar 15;87(6):2345-53.

33.

Alterations of T cell repertoire after bone marrow transplantation: characterization of over-represented subsets.

Gaschet J, Denis C, Milpied N, Hallet MM, Romagné F, Necker A, Vivien R, David-Ameline J, Davodeau F, Bonneville M, et al.

Bone Marrow Transplant. 1995 Sep;16(3):427-35.

PMID:
8535316
34.

Analysis of T-cell receptor V beta expression among V alpha subsets. Evidence for tight regulation of the combinatorial diversity.

Gaschet J, Denis C, Milpied N, Hallet MM, Davodeau F, Necker A, Romagné F, Bonneville M, Vié H.

Ann N Y Acad Sci. 1995 Jul 7;756:84-6. No abstract available.

PMID:
7645878
35.

Oligoclonal T-cell repertoire and graft-versus-host disease after allogeneic bone marrow transplantation.

Gaschet J, Milpied N, Denis C, Hallet MM, Davodeau F, Bonneville M, Vié H.

Ann N Y Acad Sci. 1995 Jul 7;756:435-7. No abstract available.

PMID:
7645867
36.

Surface expression of functional T cell receptor chains formed by interlocus recombination on human T lymphocytes.

Davodeau F, Peyrat MA, Gaschet J, Hallet MM, Triebel F, Vié H, Kabelitz D, Bonneville M.

J Exp Med. 1994 Nov 1;180(5):1685-91.

37.

Alteration of the T cell repertoire after bone marrow transplantation.

Villers D, Milpied N, Gaschet J, Davodeau F, Hallet MM, Bonneville M, Vié H.

Bone Marrow Transplant. 1994 Jan;13(1):19-26.

PMID:
8019449
38.

Close correlation between Daudi and mycobacterial antigen recognition by human gamma delta T cells and expression of V9JPC1 gamma/V2DJC delta-encoded T cell receptors.

Davodeau F, Peyrat MA, Hallet MM, Gaschet J, Houde I, Vivien R, Vie H, Bonneville M.

J Immunol. 1993 Aug 1;151(3):1214-23.

PMID:
8393042
39.

Specificity of T cells invading the skin during acute graft-vs.-host disease after semiallogeneic bone marrow transplantation.

Gaschet J, Mahé B, Milpied N, Devilder MC, Dréno B, Bignon JD, Davodeau F, Hallet MM, Bonneville M, Vié H.

J Clin Invest. 1993 Jan;91(1):12-20.

Supplemental Content

Loading ...
Support Center